Agytherix

Agytherix is a pre-clinical stage biotechnology company focused on developing targeted therapies for gastrointestinal cancers and their precursor conditions. The company's lead program is a monoclonal antibody targeting Bone Morphogenetic Protein 4 (BMP4), which plays a critical role in the progression of Barrett's esophagus to esophageal adenocarcinoma. By inhibiting the BMP4 signaling pathway, Agytherix aims to provide a novel therapeutic approach to prevent and treat highly aggressive esophageal cancers. The company is a spin-out from the University of Melbourne and St Vincent's Hospital Melbourne, leveraging deep expertise in cancer biology and signaling pathways.